Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Histoplasmosis may complicate tumor necrosis factor (TNF)-α blocker therapy. Published case series provide limited guidance on disease management. We sought to determine the need for long-term antifungal therapy and the safety of resuming TNF-α blocker therapy after successful treatment of histoplasmosis. METHODS: We conducted a multicenter retrospective review of 98 patients diagnosed with histoplasmosis between January 2000 and June 2011. Multivariate logistic regression was used to evaluate risk factors for severe disease. RESULTS: The most commonly used biologic agent was infliximab (67.3%). Concomitant corticosteroid use (odds ratio [OR], 3.94 [95% confidence interval {CI}, 1.06-14.60]) and higher urine Histoplasma antigen levels (OR, 1.14 [95% CI, 1.03-1.25]) were found to be independent predictors of severe disease. Forty-six (47.4%) patients were initially treated with an amphotericin B formulation for a median duration of 2 weeks. Azole treatment was given for a median of 12 months. TNF-α blocker therapy was initially discontinued in 95 of 98 (96.9%) patients and later resumed in 25 of 74 (33.8%) patients at a median of 12 months (range, 1-69 months). The recurrence rate was 3.2% at a median follow-up period of 32 months. Of the 3 patients with recurrence, 2 had restarted TNF-α blocker therapy, 1 of whom died. Mortality rate was 3.2%. CONCLUSIONS: In this study, disease outcomes were generally favorable. Discontinuation of antifungal treatment after clinical response and an appropriate duration of therapy, probably at least 12 months, appears safe if pharmacologic immunosuppression has been held. Resumption of TNF-α blocker therapy also appears safe, assuming that the initial antifungal therapy was administered for 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thompson, G. R., Le, T., Chindamporn, A., Kauffman, C. A., Alastruey-Izquierdo, A., Ampel, N. M., Andes, D. R., Armstrong-James, D., Ayanlowo, O., Baddley, J. W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00191-2 · Cited by 311
Self-citationDelivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
New clinical phenotypes of fungal infections in special hosts
Pilmis, B., Puel, A., Lortholary, O., & Lanternier, F. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.05.016 · Cited by 68
Histoplasmosis-associated hospitalizations in the United States, 2001–2012
Benedict, K., Derado, G., & Mody, R. K. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv219 · Cited by 51
Metadata
- Authors
- Vergidis, P., Avery, R. K., Wheat, L. J., Dotson, J. L., Assi, M. A., Antoun, S. A., Hamoud, K. A., Burdette, S. D., Freifeld, A. G., McKinsey, D. S., Money, M. E., Myint, T., Andes, D. R., Hoey, C. A., Kaul, D. A., Dickter, J. K., Liebers, D. E., Miller, R. A., Muth, W. E., Prakash, V., Steiner, F. T., Walker, R. C., & Hage, C. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-13
- Volume
- 61
- Issue
- 3
- Pages
- 409-417
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2111855467
- Cited by
- 146
- References
- 0
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases. https://app.cochat.ai/papers/10.1093/cid/civ299
- The paper
- Vergidis, P., Avery, R. K., Wheat, L. J., Dotson, J. L., Assi, M. A., Antoun, S. A., Hamoud, K. A., Burdette, S. D., Freifeld, A. G., McKinsey, D. S., Money, M. E., Myint, T., Andes, D. R., Hoey, C. A., Kaul, D. A., Dickter, J. K., Liebers, D. E., Miller, R. A., Muth, W. E., . . . Hage, C. A. (2015). Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases. Clinical Infectious Diseases. https://doi.org/10.1093/cid/civ299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.